Sign in
KPRX Stock Price, Chart, Stats & News
Kiora Pharmaceuticals, Inc.
Save
Kiora Pharmaceuticals, Inc. (KPRX) does not currently pay a dividend.
11.48M
Market cap
–
Current P/E
2.41x
Forward P/E
KPRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 10.58% |
ROA | -44.67% |
ROE | -51.37% |
D/E | 0.02x |
Interest coverage ratio | – |
KPRX valuation
P/E | – |
P/S | – |
P/B | 0.49x |
P/CF | -0.79x |
P/FCF | -0.69x |
P/OCF | -0.79x |
PEG | 0.13x |
EV multiple | -1.62x |
About
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration.
Similar securities
Based on sector and market capitalization
Report issue